RXSIGHT INC (RXST)
Health Care · Premium intraocular lens devices · NASDAQ
RxSight is the only company commercializing light-adjustable intraocular lenses that let surgeons customize patient vision after cataract surgery, eliminating pre-operative guesswork.
What RXSIGHT INC does
RxSight is a medical technology company that designs and commercializes the RxSight Light Adjustable Lens (LAL) system for cataract surgery. The system consists of a proprietary photosensitive silicone-based intraocular lens (IOL) combined with a Light Delivery Device (LDD) that allows surgeons to customize and adjust a patient's vision after surgery using UV light exposure. Unlike conventional premium IOLs that are fixed-power lenses, the RxSight system enables post-surgical refinement of visual acuity in precise 0.25 diopter increments to optimize each patient's individual vision outcomes.
Themes: Premium cataract surgery, Intraocular lens technology, Customized vision correction, Post-surgical refractive adjustment
Fundamentals
- Price$6.25 as of 2026-08-21 close
- Market cap$260M as of 2026-08-21
- 1-year return-28.4% 2025-08-21 close $8.73 → 2026-08-21 close $6.25
- P/En/a negative earnings
- Net margin-36.8% as of 2026-08-24
- Gross margin+77.5% as of 2026-08-24
- ROE-17.3% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-13.2% as of 2026-08-24
- Revenue CAGR (3y)+40.0% SEC XBRL
- Beta1.10 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How RXST compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How RXSIGHT INC looks technically
RXSIGHT INC (RXST) is trading 19.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 130 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative). It made a new 20-day high about 8 trading days ago. It is 52.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 19.5% below its 200-day average, the long-term trend line — a long-term downtrend | -19.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.63 | $5.63 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.77 | $7.77 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 5.93. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 130 trading days ago — a "death cross", a bearish long-term signal | 130 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.0 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($5.43 to $7.22) — its "stochastic" reading is 46 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 45.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 3 trading days ago (its momentum flipped negative) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.22 | $13.22 |
|---|---|---|
| From the 52-week high | it is 52.7% below its 52-week high (its highest price of the past year) | -52.7% |
| Above the 52-week low | it is 39.5% above its 52-week low (its lowest price of the past year) | +39.5% |
| Below the 52-week high | it is 52.7% below its highest point of the past year | 52.7% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $66.54 (set on 2024-05-07) | $66.54 |
| Given back of the 52-week move | over the past year its closes ranged ($4.59 to $13.09), and it has recovered roughly a quarter of its fall from last year’s high — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.84 to $10.12. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 19.5% |
| From the all-time high | it is 90.6% below its all-time high | -90.6% |
| Nearest price level | it is trading 5.2% below a resistance level at $6.58 — a price it turned at twice since 2025-08-11, most recently on 2026-05-22. Since 2024-08-21 it has 1 such level below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.2% |
| All-time low | its lowest closing price on record is $4.48 (set on 2026-06-11) | $4.48 |
| Above the all-time low | it is 39.5% above its all-time low | +39.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 72% of it) | 28th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.395 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.395 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.60 and $7.10 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.60 – $6.35 – $7.10 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 3.8 daily ranges below its 200-day average price (19.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.69× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.6% since the prior reading | -1.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 4.6% gap down opened on 2026-08-06 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 16.7 percentage points (the stock gained 19.0% while the market gained 2.3%) | +16.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.7 percentage points (the stock lost 1.6% while the market gained 3.1%) | -4.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 38.6 percentage points (the stock lost 27.6% while the market gained 11.1%) | -38.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.9 percentage points (the stock lost 28.4% while the market gained 20.5%) | -48.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 11.2% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +4.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.77 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | -7.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-07-06 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $5.89 — a volume-weighted average of daily closes over 35 sessions, not a true tick-by-tick VWAP. | +6.2% |
Price levels it has turned at before
RXST last closed at $6.25 on 2026-08-21. Since 2024-08-21 it has turned at 1 price below its last close and 8 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.58 | Resistance | 5.2% above the last close | turned there twice · 2025-08-11 to 2026-05-22 |
| $5.91 | Support | 5.4% below the last close | turned there three times · 2026-03-31 to 2026-07-16 |
| $7.18 | Resistance | 14.8% above the last close | turned there twice · 2026-02-27 to 2026-08-11 |
| $7.45 | Resistance | 19.1% above the last close | turned there twice · 2025-10-14 to 2026-05-04 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $5.93.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $6.14 and $6.71 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $7.22.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.10 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$7.79 range $6.00 – $11.00; median $6.75
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RXST
- Consensus EPS estimate-$0.1533 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of net losses and ongoing unprofitability; the company incurred net losses and expects to continue incurring losses in the future, with limited path to profitability evident in current financials (net margin -36.59%).","Dependence on single and sole-source suppliers for critical components and subcomponents of the RxSight system, creating vulnerability to supply disruptions and price fluctuations.","Reliance on sales force effectiveness and cost-efficient marketing to drive adoption; failure to effectively train and scale sales capabilities or establish broad brand awareness could impede growth, particularly given 14% YoY revenue decline."]
What changed in the latest 10-Q
AI-assisted comparison of RXST's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Item 2 page number changed from 24 (2025-11-05 filing) to 25 (2026-05-06 filing)
- Item 3 page number changed from 34 (2025-11-05 filing) to 33 (2026-05-06 filing)
- Item 4 page number changed from 35 (2025-11-05 filing) to 33 (2026-05-06 filing)
- Item 1 under PART II page number changed from 35 (2025-11-05 filing) to 34 (2026-05-06 filing)
- Notes:
- This comparison is limited to a table of contents/section header structure; substantive MD&A content is not provided in the source texts
- Page number changes may reflect document reformatting or content additions/deletions elsewhere in the filing
Risk Factors
- Added:
- Newer filing (filed 2026-05-06) adds page number '35' after the Summary Risk Factors section.
- Removed:
- Older filing (filed 2025-11-05) includes bullet point 'We may experience a significant disruption in our information technology systems or breaches of data security.' under Risks related to our business and products; this is removed in newer filing.
- Older filing (filed 2025-11-05) contains wording 'We have a history of net operating losses' which is changed to 'We have a history of net losses' in newer filing.
- Older filing (filed 2025-11-05) contains wording 'In order to support our continued operations' which is changed to 'To support our continued operations' in newer filing.
- Older filing (filed 2025-11-05) contains wording 'We intend to expand sales of our products internationally in the future' which is changed to 'We have commenced and intend to expand in the future, sales of our products internationally' in newer filing.
- Reworded:
- Newer filing (filed 2026-05-06): 'We have a history of net losses' replaces older filing's 'We have a history of net operating losses'
- Newer filing (filed 2026-05-06): 'To support our continued operations' replaces older filing's 'In order to support our continued operations'
- Newer filing (filed 2026-05-06): 'We have commenced and intend to expand in the future, sales of our products internationally' replaces older filing's 'We intend to expand sales of our products internationally in the future'
- Notes:
- Both filings appear truncated at the end of the detailed risk factor text; full comparison of complete risk factor sections is not possible.
- Page numbering differs between filings (page 35 vs 36-37), suggesting possible document formatting or section reorganization.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for RXST — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding RXST as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,229,081
- Reported value $32,211,142
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
RXST had 4,056,607 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
RXST had 9.75% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.04 days to cover at the same settlement.
- Reported short interest (shares) 4,056,607
- Short interest (% of shares outstanding) 9.75%
- Prior settlement (shares) 3,841,752
- Reported change 5.59%
- Days to cover (reported) 4.04
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alcon (ALC)
- Johnson & Johnson MedTech (JNJ)
- Bausch + Lomb (BLCO)
- Carl Zeiss Meditec (AFX.DE)
- STAAR Surgical (STAA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare RXST vs…
Frequently asked questions
What does RXSIGHT INC (RXST) do?
RxSight is a medical technology company that designs and commercializes the RxSight Light Adjustable Lens (LAL) system for cataract surgery. The system consists of a proprietary photosensitive silicone-based intraocular lens (IOL) combined with a Light Delivery Device (LDD) that allows surgeons to customize and adjust a patient's vision after surgery using UV light exposure.
What sector is RXSIGHT INC (RXST) in?
RXSIGHT INC (RXST) is classified in the Health Care sector. Its industry is Premium intraocular lens devices. It trades on NASDAQ.
Who are RXSIGHT INC's (RXST) competitors?
Notable peers of RXSIGHT INC (RXST) include Alcon, Johnson & Johnson MedTech, Bausch + Lomb, Carl Zeiss Meditec and STAAR Surgical. This peer set is informational only — not financial advice.
Is RXSIGHT INC (RXST) overbought or oversold right now?
RXSIGHT INC (RXST) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RXST come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.